11630 RESULTS
COMMENT Aducanumab may work because it reduces both insouble and soluble Abeta. However it may be incorrect to believe that the beneficial effect can only be manifest in early or prodromal disease because there is too much damage in more advanced cases. Instead i
COMMENT These findings were was novel to me, and show how the immune system is always surprising us. Systemic inflammation needs to be taken into account when considering cell-based therapy. There are multiple clinical trials planned for treatment of Parkinson’s
COMMENT I met Rahul at a conference for early investigators several years back, and we all found it easy to become his colleague and friend. I was struck by his seemingly boundless energy, intelligence, and creativity. It's difficult for me to process the lo
COMMENT therapeutic outcomes. —Gerhard Leinenga is co-author of this comment. j.goetz 0 A comparative study of the
COMMENT We appreciate the insightful comment by Drs. Ezzat and Espay and are grateful that our colleagues
